Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IC 800

            Therapeutic Area: Ophthalmology Product Name: IC 800

            Highest Development Status: Preclinical Product Type: Undisclosed

            Partner/Sponsor/Collaborator: IACTA PHARMACEUTICALS

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration January 07, 2021

            Details:

            Under the terms of these agreements, Pharmaleads and Pharmaleads Greater China have granted IACTA an exclusive, worldwide, royalty-bearing license to lead the clinical and commercial development of IC800 (acute) and IC805 and other DENKI drugs from Pharmaleads’ portfolio.